AI Stock Picks — June 10, 2026

The 5 AI-selected stock picks for June 10, 2026 from StocksRankings — with full investment thesis, bull case, bear case, and key catalyst for each.

5 AI Stock Picks for June 10, 2026

1. AMAT — Applied Materials [Top Performer]
   Applied Materials, a leader in semiconductor manufacturing equipment, will benefit from continued capital investment in advanced chip fabrication as highlighted by Amazon's logistics expansion and persistent demand for AI hardware. The company's Endura platform, which enables atomic-level precision in chipmaking, underpins its dominant market share and drives recurring service revenue. With a 1-year return of +204.55%, momentum remains strong, and the capital intensity of next-generation nodes supports further earnings growth despite a volatile macro backdrop.
   Key risk: A sharp pullback in semiconductor capital expenditures from major foundries would reduce equipment orders and pressure margins.
2. CHTR — Charter Communications [Contrarian Value]
   Charter Communications, a leading U.S. broadband and cable operator, stands to gain from ongoing demand for high-speed internet as Amazon's logistics expansion increases digital infrastructure needs. The company's hybrid fiber-coax network reaches over 30 million customers, and recent $3.8M in insider buying signals management conviction in a recovery. The P/E ratio of 3.63x and forward EPS growth of 14.5% indicate the market is pricing in excessive pessimism, offering asymmetric risk-reward if execution stabilizes.
   Key risk: Aggressive overbuilds by fiber competitors or wireless 5G fixed broadband could accelerate subscriber losses and compress margins.
3. ABBV — AbbVie [Lowest PEG]
   AbbVie, a global biopharmaceutical company, is positioned for earnings growth as its immunology and neuroscience franchises offset Humira biosimilar erosion, and the company continues to execute on new launches. Skyrizi and Rinvoq, which together generated over $10B in 2025 sales, are gaining share in autoimmune indications and driving revenue diversification. The PEG ratio of 0.17 and 668% EPS growth signal that AbbVie's valuation does not reflect its forward earnings trajectory, making it attractive in a defensive sector during periods of elevated volatility.
   Key risk: Unexpected safety or regulatory setbacks for Skyrizi or Rinvoq could undermine the growth thesis and pressure future earnings.

See today's picks · full picks history · AI pick track record